Table 3.
Correlation of Maternal and Fetal Metabolites
| Maternal | Fetal | C | T | T-Flutamide | T-Rosi | |
|---|---|---|---|---|---|---|
| FFA (maternal) | Arachidic acid (20:0) | Arachidonic acid (20:4) | 0.928a | 0.314 | 0.030 | 0.030 |
| Amino acids (maternal) | Glycine | Palmitic acid (16:0) | 0.829a | 0.086 | 0.086 | −0.880a |
| Sarcosine | Decenoyl-(C10:1) | −0.890a | −0.543 | −0.77b | −0.200 | |
| Ornithine | Oleic acid (18:1 [n-9]) | −0.600 | −0.890a | −0.200 | −0.770b | |
| Tryptophan | Octenoyl-(C8:1) | −0.928a | 0.971a | 0.152 | −0.920a | |
| Tryptophan | 3-Hydroxyoctadecadienyl- (C18:2-OH) | −0.820a | 0.029 | −0.370 | −0.840a | |
| Acylcarnitines (maternal) | Tetradecanoyl-(C14) | Valine | 0.943a | 0.486 | −0.480 | 0.771b |
| Tetradecanoyl-(C14) | Leucine | 0.943a | 0.600 | −0.200 | 0.886a | |
| Hexadecanoyl-(C16) | α-Aminoisobutyric acid | 0.829a | 0.086 | −0.480 | 1.000a | |
| 3-Hydroxyhexadecanoyl- (C16-OH) | Isoleucine | 0.986a | 0.500 | 0.812a | 0.638 | |
| Isovaleryl-(C5) | Methionine | −0.943a | −0.147 | 0.086 | −0.830a | |
| Tetradecadienoyl-(C14:2) | α-Aminoisobutyric acid | −0.829a | 0.029 | −0.810a | −0.230 | |
| Isovaleryl-(C5) | Arachidoyl-(C20:2) | −0.899a | 0.179 | −0.690b | 0.154 | |
| Tetradecanoyl-(C14) | Tetradecadienyl-(C14:2) | −0.870a | −0.841a | 0.200 | 0.829a | |
| Octadecadienyl-(C18:2) | Glutaryl-(C5-DC) | −0.971a | −0.338 | 0.171 | −0.760b | |
| Arachidoyl-(C20) | Butyryl-(C4) | −0.899a | −0.116 | −0.090 | 0.029 |
Abbreviations: C, controls; T, treated with T; T-Flutamide, treated with T plus flutamide; T-Rosi, treated with T plus rosiglitazone.
a
A significant correlation between both metabolites within treatment group.
b
A tendency (from P > .05 to P < .08) in the correlation between both metabolites within treatment group.